Karolinska Developments portföljbolag Biosergen publicerar prospekt i samband med emission av units
March 14, 2024 06:24 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 14 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Biosergen publicerat ett prospekt med anledning av en företrädesemission av units som...
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units
March 14, 2024 06:24 ET
|
Karolinska Development AB (publ)
STOCKHOLM, Sweden, March 14 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has published a prospectus for the issue of units that was approved...
Karolinska Developments portföljbolag Umecrine Cognition presenterar prekliniska Parkinsondata för golexanolon på AD/PD
March 06, 2024 03:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 6 mars 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar nyligen genererade prekliniska resultat som belyser...
Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD
March 06, 2024 03:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – March 6, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present recent nonclinical data elucidating...
Bokslutskommuniké för januari – december 2023
February 16, 2024 02:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM – den 16 februari 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin bokslutskommuniké för januari – december 2023. Den fulla rapporten är tillgänglig på bolagets...
Year-end Report - January-December 2023
February 16, 2024 02:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM – 16 February 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report - January-December 2023. The full report is available on the Company's website. ...
Karolinska Developments portföljbolag AnaCardio säkrar 50 MSEK inom ramarna för sin serie A-finansieringsrunda
January 17, 2024 06:25 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 17 januari 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har erhållit 50 miljoner kronor i den andra och avslutande delen av...
Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round
January 17, 2024 06:25 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN January 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has received the second tranche of SEK 50 million,...
Karolinska Developments portföljbolag OssDsign rapporterar exceptionella kliniska data för sitt nanosyntetiska bengraft
January 09, 2024 11:52 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 9 januari 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign rapporterat positiva data från den kliniska studien TOP FUSION....
Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product
January 09, 2024 11:52 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line...